Physician profile
Robert T Stevenson
NPI 1225244684
$4,845.41
in general payments reported to CMS, 2019-2025
26 companies · $689 in 2025
The $689 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $396 · 2021: $236 · 2022: $813 · 2023: $661 · 2024: $624 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $673.00 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $604.82 | 2019-2025 | Farapulse, Emblem Mri S-Icd, Reliance 4-Front |
| Biotronik INC. | $396.97 | 2019-2025 | Acticor 7 Vr-T Dx |
| Pfizer INC. | $366.02 | 2019-2025 | |
| Medtronic Vascular, INC. | $339.10 | 2019 | |
| Amgen INC. | $326.63 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.22 | 2019-2025 | Lifevest |
| Medtronic, INC. | $265.69 | 2021-2024 | Micra, Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.98 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $196.84 | 2019-2025 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $195.67 | 2022-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $187.77 | 2019-2025 | Farxiga, Lokelma |
| Baxter Healthcare | $152.22 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $133.28 | 2019-2024 | |
| Chiesi USA, INC. | $84.05 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $69.42 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $62.85 | 2022-2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $51.59 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $47.40 | 2024 | Assure Wcd |
| Abbott Laboratories | $45.50 | 2019-2025 | Jot Dx |
| Abiomed | $38.28 | 2020-2021 | |
| Teleflex LLC | $25.09 | 2025 | Guideliner |
| Bridgebio Pharma, INC. | $23.50 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $17.86 | 2023 | Inpefa |
| Amarin Pharma, INC. | $15.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.